BFRI vs. OCX, OKYO, OMGA, SLGL, PMN, RNXT, AKTX, IXHL, LSTA, and CGTX
Should you be buying Biofrontera stock or one of its competitors? The main competitors of Biofrontera include OncoCyte (OCX), OKYO Pharma (OKYO), Omega Therapeutics (OMGA), Sol-Gel Technologies (SLGL), ProMIS Neurosciences (PMN), RenovoRx (RNXT), Akari Therapeutics (AKTX), Incannex Healthcare (IXHL), Lisata Therapeutics (LSTA), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry.
Biofrontera vs.
OncoCyte (NASDAQ:OCX) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends.
OncoCyte currently has a consensus target price of $4.42, indicating a potential upside of 112.34%. Biofrontera has a consensus target price of $7.00, indicating a potential upside of 536.36%. Given Biofrontera's stronger consensus rating and higher possible upside, analysts clearly believe Biofrontera is more favorable than OncoCyte.
In the previous week, OncoCyte had 2 more articles in the media than Biofrontera. MarketBeat recorded 2 mentions for OncoCyte and 0 mentions for Biofrontera. OncoCyte's average media sentiment score of 1.46 beat Biofrontera's score of 0.00 indicating that OncoCyte is being referred to more favorably in the media.
Biofrontera has higher revenue and earnings than OncoCyte.
OncoCyte received 1 more outperform votes than Biofrontera when rated by MarketBeat users. However, 66.67% of users gave Biofrontera an outperform vote while only 8.33% of users gave OncoCyte an outperform vote.
OncoCyte has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500.
Biofrontera has a net margin of -36.31% compared to OncoCyte's net margin of -6,122.29%. OncoCyte's return on equity of -269.32% beat Biofrontera's return on equity.
55.4% of OncoCyte shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 1.6% of OncoCyte shares are held by insiders. Comparatively, 0.2% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
OncoCyte beats Biofrontera on 10 of the 16 factors compared between the two stocks.
Get Biofrontera News Delivered to You Automatically
Sign up to receive the latest news and ratings for BFRI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biofrontera Competitors List
Related Companies and Tools
This page (NASDAQ:BFRI) was last updated on 1/21/2025 by MarketBeat.com Staff
